Financial Summary

Aprea Therapeutics Inc  (APRE)  $26.45    (%)

  • Symbol
    APRE
    Price
    26.45$
    Beta
    0
    Volume Avrg.
    151519
    Market Cap
    560390850
    Last Div
    0
    Range
    19.67-53.11
    Changes
    2.45
    Changes Percentage
    Exchange
    NasdaqGS
    Industry
    Biotechnology
    Ceo
    Mr. Christian S. Schade
    Sector
    Healthcare

About company

Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 14 full-time employees. The firm is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate, APR-246, is a small molecule p53 reactivator that is being developed for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). APR-246 product candidate is designed to be administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one (MQ), under physiological conditions. Its second product candidate, APR-548, is a p53 reactivator. APR-548 is being developed in an oral dosage form.


Income Statement

YearRevenueCost of revenuesGross profitOperating expensessOperating incomesInterest expenseIncome tax expensesEarnings before taxsNet incomeEarnings per share basicsEarnings per share dilutedsDividend per sharesGross marginsEBIT marginsProfit marginsEBITDAEBITEarnings Before Tax MarginsNet Profit Margins
2020220747.00 151286.00 104956.00 38668.0066288.002873.00968.0067091.0057411.003.308587268217793.280.8033334143460.4754583301250.3002894716580.26007601462377344.0066288.000.3039271201870.260076014623
2019260174.00 161782.00 98392.00 34462.006393.003576.0010481.0065737.0055256.0011.9711.893.037054038220.378177681090.2457201718850.2123809450676477.006393.000.2526655238420.21238094506
2018265595.00 163756.00 101839.00 30941.0070898.00324.0013372.0072903.0059531.0012.0111.912.742340216980.38343718820.2669402661950.22414202074681801.0070898.000.2744893540920.224142020746
2017229234.00 141048.00 88186.00 26842.0061344.002323.0015738.0064089.0048351.009.279.212.431406868490.3846986049190.2676042820870.21092420845171501.0061344.000.2795789455320.210924208451
2016215639.00 131376.00 84263.00 24239.0060024.001456.0015685.0061372.0045687.008.358.312.208978050390.3907595564810.2783541010670.21186798306470529.0060024.000.2846052893960.211867983064
2015233715.00 140089.00 93626.00 22396.007123.00733.0019121.0072515.0053394.009.289.221.995660676580.4005990201740.3047729071730.22845773698782487.007123.000.3102710566290.228457736987
2014182795.00 112258.00 70537.00 18034.0052503.00384.0013973.0053483.003951.006.496.451.8171831440.3858803577780.2872233923250.21614376760960449.0052503.000.2925845892940.216143767609
201317091.00 106606.00 64304.00 15305.0048999.00136.0013118.0050155.0037037.0040.0339.7511.3388761160.3762448072080.2866947516240.21670469837955756.0048999.000.2934585454330.216704698379
2012156508.00 87846.00 68662.00 13421.0055241.000.001403.0055763.0041733.0044.6444.152.631815561350.4387123980880.352959593120.26665090602458518.0055241.000.3562948858840.266650906024
2011108249.00 64431.00 43818.00 10028.003379.000.008283.0034205.0025922.0028.0527.680.00.4047889587890.3121506896140.23946641539435604.003379.000.3159844432740.239466415394
201065225.00 39541.00 25684.00 7299.0018385.000.004527.001854.0014013.0015.4115.150.00.3937753928710.2818704484480.21484093522419412.0018385.000.2842468378690.214840935224
200942905.00 25683.00 17222.00 5482.001174.000.003831.0012066.008235.001.3171.2970.00.40140.28120.192128.0012066.000.28120.1919
Year202020192018201720162015201420132012201120102009
Revenue220747.00260174.00265595.00229234.00215639.00233715.00182795.0017091.00156508.00108249.0065225.0042905.00
Cost of revenues151286.00161782.00163756.00141048.00131376.00140089.00112258.00106606.0087846.0064431.0039541.0025683.00
Gross profit 104956.00 98392.00 101839.00 88186.00 84263.00 93626.00 70537.00 64304.00 68662.00 43818.00 25684.00 17222.00
Operating expensess38668.0034462.0030941.0026842.0024239.0022396.0018034.0015305.0013421.0010028.007299.005482.00
Operating incomes66288.006393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.001174.00
Interest expense2873.003576.00324.002323.001456.00733.00384.00136.000.000.000.000.00
Income tax expenses968.0010481.0013372.0015738.0015685.0019121.0013973.0013118.001403.008283.004527.003831.00
Earnings before taxs67091.0065737.0072903.0064089.0061372.0072515.0053483.0050155.0055763.0034205.001854.0012066.00
Net income57411.0055256.0059531.0048351.0045687.0053394.003951.0037037.0041733.0025922.0014013.008235.00
Earnings per share basics3.3085872682177911.9712.019.278.359.286.4940.0344.6428.0515.411.317
Earnings per share diluteds3.2811.8911.919.218.319.226.4539.7544.1527.6815.151.297
Dividend per shares0.83.042.742.432.2121.8211.342.63000
Gross margins0.480.380.380.380.390.40.390.380.440.40.390.4
EBIT margins0.30.250.270.270.280.30.290.290.350.310.280.28
Profit margins0.260.210.220.210.210.230.220.220.270.240.210.19
EBITDA77344.0076477.0081801.0071501.0070529.0082487.0060449.0055756.0058518.0035604.0019412.00128.00
EBIT66288.006393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.0012066.00
Earnings Before Tax Margins0.30.250.270.280.280.310.290.290.360.320.280.28
Net Profit Margins0.260.210.220.210.210.230.220.220.270.240.210.19